Coherus BioSciences Is To Takeover Surface Oncology
- June 16th, 2023
- 354 views
Coherus BioSciences, Inc. (Nasdaq: CHRS) and Surface Oncology, Inc. (Nasdaq: SURF) have entered into a definitive merger agreement where Coherus will acquire Surface Oncology in a stock for stock transaction valued at up to $65 million.
This merger will add two clinical-stage assets, SRF388 and SRF114, to Coherus' immuno-oncology pipeline.
The agreement involves Coherus issuing shares of its common stock at a price of $5.2831 per share to acquire all outstanding shares of Surface stock. Surface shareholders will also receive contingent value rights (CVRs) tied to milestone and royalty-based values.
The merger is expected to have a positive financial impact, with Surface's net cash projected to strengthen Coherus' balance sheet. Additionally, the acquisition will enable pipeline prioritization and reduce R&D spending.
In pre-market, $SURF is trading at $1.01 (+36.48%), while $CHRS is trading at $5.07 (-5.94%), following the announcement.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Johnson & Johnson, Charles Schwab, Halliburton: Earnings Preview
January 18th, 2026Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026
Member Login